Nothing Special   »   [go: up one dir, main page]

BR112016024020A8 - composição farmacêutica - Google Patents

composição farmacêutica

Info

Publication number
BR112016024020A8
BR112016024020A8 BR112016024020A BR112016024020A BR112016024020A8 BR 112016024020 A8 BR112016024020 A8 BR 112016024020A8 BR 112016024020 A BR112016024020 A BR 112016024020A BR 112016024020 A BR112016024020 A BR 112016024020A BR 112016024020 A8 BR112016024020 A8 BR 112016024020A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
fatty liver
liver disease
thiomorpholin
tetrahydropyran
Prior art date
Application number
BR112016024020A
Other languages
English (en)
Other versions
BR112016024020A2 (pt
Inventor
Sul Park Heui
Kyun Chung Hyo
Jin Kim Hyoung
Ho Shong Min
Hyun Ahn Seo
Ha Kim Soo
Original Assignee
Lg Chemical Ltd
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd, Lg Life Sciences Ltd filed Critical Lg Chemical Ltd
Publication of BR112016024020A2 publication Critical patent/BR112016024020A2/pt
Publication of BR112016024020A8 publication Critical patent/BR112016024020A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composição farmacêutica. a presente invenção refere-se a uma composição farmacêutica para prevenção ou tratamento de doença hepática gordurosa, contendo (tetra-hidropiran-4-il)-[2-fenil-5-(1,1-dioxo-tiomorfolin-4-il)metil-1h-indol-7-il]amina, ou um sal farmaceuticamente aceitável do mesmo, como ingredientes ativos. o (tetra-hidropiran-4-il)-[2-fenil-5-(1,1-dioxo-tiomorfolin-4-il)metil-1h-indol-7-il]amina ou um sal farmaceuticamente aceitável do mesmo, de acordo com a presente invenção, pode eficazmente inibir o fígado gorduroso, hepatite e fibrose hepática e pode ser usada para prevenção ou tratamento de nafld (doença hepática gordurosa não alcoólica), e em particular, a nash (esteatose hepática não alcoólica).
BR112016024020A 2014-04-18 2015-04-17 composição farmacêutica BR112016024020A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140046904 2014-04-18
PCT/KR2015/003869 WO2015160213A1 (ko) 2014-04-18 2015-04-17 지방간 질환의 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
BR112016024020A2 BR112016024020A2 (pt) 2017-08-15
BR112016024020A8 true BR112016024020A8 (pt) 2021-07-20

Family

ID=54324325

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024020A BR112016024020A8 (pt) 2014-04-18 2015-04-17 composição farmacêutica

Country Status (10)

Country Link
US (1) US9814726B2 (pt)
EP (1) EP3132795B1 (pt)
JP (1) JP6490097B2 (pt)
KR (1) KR102006247B1 (pt)
CN (2) CN113967215A (pt)
BR (1) BR112016024020A8 (pt)
ES (1) ES2851006T3 (pt)
MX (1) MX369571B (pt)
RU (1) RU2664696C2 (pt)
WO (1) WO2015160213A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019111048A1 (en) * 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
JPWO2021107029A1 (pt) * 2019-11-26 2021-06-03
CN115361866A (zh) * 2020-03-31 2022-11-18 株式会社Lg化学 用于保护胰岛移植的组合物
WO2022039506A1 (ko) 2020-08-19 2022-02-24 주식회사 미토이뮨테라퓨틱스 Ｍabc-r 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
CN114470217B (zh) * 2020-11-24 2023-06-20 深圳微芯生物科技股份有限公司 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物
WO2022220518A1 (ko) 2021-04-12 2022-10-20 주식회사 미토이뮨테라퓨틱스 5-[(1,1-디옥시도-4-티오몰포리닐)메틸]-2-페닐-n-(테트라하이드로-2h-피란-4-일)-1h-인돌-7-아민 황산염 및 이의 신규 결정형
KR20220141251A (ko) 2021-04-12 2022-10-19 주식회사 미토이뮨테라퓨틱스 5-[(1,1-디옥시도-4-티오몰포리닐)메틸]-2-페닐-n-(테트라하이드로-2h-피란-4-일)-1h-인돌-7-아민의 신규 결정형
JP2024530919A (ja) 2021-08-02 2024-08-27 ミトイミューン・セラピューティクス・インコーポレイテッド 新規のインドール誘導体、これを含む薬学的組成物、およびその用途
KR20230019797A (ko) 2021-08-02 2023-02-09 주식회사 미토이뮨테라퓨틱스 인돌 유도체, 이의 제조방법 및 약학적 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1873144B1 (en) * 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US20070161578A1 (en) * 2005-12-21 2007-07-12 Hwa Joyce J Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
KR20090018593A (ko) * 2007-08-17 2009-02-20 주식회사 엘지생명과학 세포괴사 저해제로서의 인돌 및 인다졸 화합물
EP2636404B1 (en) * 2007-11-30 2019-03-20 The Regents of The University of California Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products
WO2009088192A2 (ko) * 2008-01-04 2009-07-16 Lg Life Sciences Ltd. 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체
ES2738101T3 (es) * 2009-07-31 2020-01-20 Smc Global Asset Inc Ratón modelo de esteatohepatitis-cáncer de hígado
TW201119651A (en) * 2009-10-26 2011-06-16 Lg Life Sciences Ltd Pharmaceutical composition comprising indole compound
KR101404151B1 (ko) 2011-11-25 2014-06-05 가톨릭대학교 산학협력단 안과 질환의 예방 및 치료용 약학 조성물
KR20130087283A (ko) * 2012-01-27 2013-08-06 재단법인 의약바이오컨버젼스연구단 인돌 및 인다졸 유도체를 유효성분으로 포함하는 암 전이 억제용 조성물
KR101413207B1 (ko) 2012-06-14 2014-07-01 부산대학교 산학협력단 염증성 질환의 예방 또는 치료용 약학 조성물 및 건강기능식품

Also Published As

Publication number Publication date
RU2664696C2 (ru) 2018-08-21
RU2016145066A3 (pt) 2018-05-20
US9814726B2 (en) 2017-11-14
MX369571B (es) 2019-11-12
CN113967215A (zh) 2022-01-25
RU2016145066A (ru) 2018-05-20
KR102006247B1 (ko) 2019-08-01
JP2017511373A (ja) 2017-04-20
EP3132795A1 (en) 2017-02-22
KR20150120877A (ko) 2015-10-28
MX2016013575A (es) 2017-06-08
WO2015160213A1 (ko) 2015-10-22
EP3132795B1 (en) 2020-10-21
CN106659722A (zh) 2017-05-10
EP3132795A4 (en) 2017-11-29
BR112016024020A2 (pt) 2017-08-15
ES2851006T3 (es) 2021-09-02
US20170035776A1 (en) 2017-02-09
JP6490097B2 (ja) 2019-03-27

Similar Documents

Publication Publication Date Title
BR112016024020A8 (pt) composição farmacêutica
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
DOP2018000182A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
BR112014031306A2 (pt) composição farmacêutica e respectivos usos
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
EA201891739A1 (ru) ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH)
BR112015028884A2 (pt) tratamento ou prevenção de depressão utilizando mentol e/ou icilina
IN2013MU01155A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]